The reductive metabolism of halothane was studied in 34 The relationship between halothane biotransformation and hepatotoxicity has received considerable attention since 1964, when the first reports of halothane metabolism were published by Stier et al. 1 and Van Dyke and co-workers. 2 Subsequent animal investigations into the mechanism underlying halothane-associated liver injury have not revealed any single factor which leads to cell death. Rather, there appear to be different mechanisms which probably vary in relative importance among species, and under different experimental conditions. There is strong evidence to suggest that under some circumstances, hepatocellular injury in experimental animals is mediated directly by reactive metabolites of halothane. In rats, hepatotoxicity is most closely associated with a reactive intermediate arising during the reductive metabolism of halothane to inorganic fluoride, 2-chloro I, l-difluoroethylene (CDF) and 2-chloro 1,1,1-trifluoroethane (CTF). anaesthesia.
The relationship between halothane biotransformation and hepatotoxicity has received considerable attention since 1964, when the first reports of halothane metabolism were published by Stier et al. 1 and Van Dyke and co-workers. 2 Subsequent animal investigations into the mechanism underlying halothane-associated liver injury have not revealed any single factor which leads to cell death. Rather, there appear to be different mechanisms which probably vary in relative importance among species, and under different experimental conditions. There is strong evidence to suggest that under some circumstances, hepatocellular injury in experimental animals is mediated directly by reactive metabolites of halothane. In rats, hepatotoxicity is most closely associated with a reactive intermediate arising during the reductive metabolism of halothane to inorganic fluoride, 2-chloro I, l-difluoroethylene (CDF) and 2-chloro 1,1,1-trifluoroethane (CTF).3 Pretreatment of animals with the enzyme-inducing drug phenobarbitone stimulates the reductive pathway of halothane metabolism and exacerbates liver injury. 4 Reductive metabolism of halothane has been observed in humans undergoing surgical anaesthesia. 5 There is also evidence of a second mechanism of injury involving an immune response, initiated by reactive intermediates arising from halothane oxidation. 6 ,7 In animal models of halothane hepatotoxicity, factors influencing the rate and route of halothane metabolism also influence the extent ofliver injury. Whether a similar relationship exists in humans is unknown. We therefore measured the extent of halothane reduction in a series of surgical patients, with the aim of determining both the incidence of this metabolic pathway and the influence of patient characteristics on its activity.
MATERIALS AND METHODS

Subject selection
The extent of halothane metabolism via the reductive pathway was measured in 34 patients undergoing halothane anaesthesia for routine surgery at the Flinders Medical Centre. The patients conformed to ASA class 1 or 2, having no organ disease other than that being corrected by surgery. None of the patients had a history ofliver disease or of unexplained fever or jaundice following a previous exposure to halothane. The study was approved by the Flinders Medical Centre Committee on Clinical Investigation.
Anaesthetic procedure
Anaesthesia was induced with thiopentone sodium 5 mg/kg and suxamethonium 1.0-1.5 mg/kg. Patients were then intubated and placed on a circle system with carbon dioxide absorber, and received intermittent positive pressure ventilation under neuromuscular blockade. Oxygen and nitrous oxide were delivered at flow rates of2litresl minute and 4litres/minute respectively. Halothane was administered via a Fluotec Mk 3 vaporiser calibrated by gas chromatography against halothane vapour standards. As the anaesthetist varied the inspired halothane concentration according to the patient's requirements, the dial setting of the vaporiser was recorded, enabling calculation of the concentration and dose of halothane delivered to the patient.
Breath sampling procedure
End-expired breath samples were collected via a 14-gauge PVC catheter, the tip of which was placed in the endotracheal tube. The sampling procedure was initiated by closing the expiratory valve and filling the reservoir bag with fresh gas mixture. The fresh gas supply was then turned off and the patient was hyperventilated manually for five breaths to achieve circuitlalveoloar gas equilibrium. A glass syringe was flushed out twice with the circuit gas, after which a 20 ml sample was withdrawn and the syringe sealed. Finally, the fresh gas supply to the circuit was turned back on. Breath was sampled at 20 and 40 minutes post-intubation, and then at ten minute intervals until at least 80 minutes after the commencement of anaesthesia. If the duration of surgery was sufficient, samples were collected up to a maximum of 120 minutes post-intubation. The concentration of CTF in breath samples was measured by gas chromotography as described by Plummer et al. 8 The area under the CTF concentration versus time curve from the commencement of halothane administration to the time of the last breath sample was calculated by the trapezoidal rule,9 giving a value of CTF exhalation in units of ppm.minutes.
Urine sampling procedure
Patients were usually admitted to hospital late on the day before surgery was scheduled, so it was not possible to collect preoperative urine over a full 24 hours. Urine was collected from each patient in polythene bottles for 12 hours, starting at 20:00 hours on that preoperative day. Urine was also collected for 24 hours postoperatively, commencing from the time of intubation. The total volume of urine was measured and an aliquot withdrawn and stored frozen. Urinary fluoride concentrations in pre-and postoperative urine samples were measured with an Orion ion selective electrode and expressed in terms of J.l.mol excreted per kilogram of body weight.
Analysis of data
Patient records were examined and the age, sex and weight were recorded, together with details of the patients' tobacco and ethanol consumption, previous exposure to general anaesthetics, use of prescribed drugs, and the maximum halothane concentration administered during the operation. These variables were examined for influence on postoperative urinary fluoride excretion and CTF exhalation by regression analysis. A multiple regression equation was constructed using the stepwise procedure for variable selection. to Covariates used with respect to postoperative urinary fluoride excretion were preoperative urinary fluoride excretion and the dose (MAC.hours) of halothane administered during the operation. Covariates used with respect to CTF exhalation were the time-weighted average halothane concentration during the breath sampling period, and the duration of the breath sampling period. These covariates were included in the equation regardless of whether they met the entry or removal criteria, because they were assumed a priori to influence the amount of halothane metabolised. Variables were added to the model if they improved fit at a significance level of below 0.05 and removed at a significance level above 0.10.
RESULTS AND DISCUSSION
Summary data are shown in Table 1 . There were 13 male and 21 female subjects ranging in weight from 51 to 147 kg. Eleven subjects were smokers and seventeen reported consuming ethanol; details of ethanol consumption could not be obtained from one case. Three patients were taking medication reported to be capable of influencing the activity of the hepatic mixed-function oxidase system. One took cimetidine, II the second took phenytoin and carbamazepine t2 ,t3 and the third received phenytoin. A further patient was receiving thyroxine for treatment of hypothyroidism which has been reported to influence the rate of halothane metabolism. t4 All but two patients had previously undergone general anaesthesia. However, previous anaesthetic records were unobtainable in 22 cases so it was impossible to determine whether these individuals had prior exposure to halothane. Records were available for five patients who were known to have previously undergone halothane anaesthesia. A period ranging from five weeks to one year had elapsed between the previous halothane anaesthetic and the study.
CTF exhalation
During halothane anaesthesia, patients exhaled concentrations of volatile reduced halothane metabolites similar to those previously reported by Sharp et aI., t5 Cousins et al. 4 3 . anaesthesia and then tended towards a plateau level, which varied considerably among individuals. CTF exhalation ranged from 2.0 to 281.8 ppm.min, with a mean of 49.3 ppm.min. In the final regression model of CTF exhalation, one variable (phenytoin intake) had a significant (P < 0.05) influence, being associated with increased CTF exhalation in the two subjects receiving the drug preoperatively. Their values of 282 and 175 ppm.min were the two highest recorded in the study. Phenytoin is a recognised enzyme inducer in man, enhancing its own metabolism and that of other compounds including warfarin, antipyrine and theophylline. 12 ,17 However, phenytoin does not influence halothane metabolism in rats,18 which suggests that the substrate specificity of phenytoin-inducible isozymes of cytochrome P-450 varies among species.
The finding of more extensive halothane reduction in patients taking phenytoin is of interest, especially in view of recent evidence that enzyme-induced patients are at greater risk of halothane hepatotoxicity. Nomura et al. 19 examined the clinical records of 279 patients anaesthetised with halothane for brain surgery. Seven out of one hundred patients taking phenobarbitone preoperatively suffered an adverse hepatic reation which was attributed to halothane, with two fatalities, compared to one hepatic reaction among 179 patients who were not receiving enzyme inducers.
While phenytoin intake exerted the greatest influence, CTF exhalation also tended to increase with time-weighted average halothane concentration and as the duration of the breathsampling period grew longer. Nevertheless, the combined influence of these three variables was insufficient to account for much of the amongpatient variation in CTF exhalation. The value (0.28) of adjusted R2 for the regression model was low, suggesting that CTF exhalation was influenced by additional factors which were not investigated in the present study. Cascorbi 
Urinary fluoride excretion
Urinary fluoride excretion is not a direct index of halothane reduction. The pharmacokinetics of fluoride disposition are complicated by absorption and release of fluoride from skeletal tissue and also by dietary fluoride intake.24 Preoperative urinary fluoride excretion of patients was therefore used as a covariate in an attempt to diminish the influence of these factors. The success of this approach was confirmed by the regression model, in which preoperative urinary fluoride excretion (mean = 0.83 IlmoVkg/24 hr) showed a highly significant (P < 0.05) association with postoperative excretion (mean = 1.04 Ilmol/kg/24 hr).
Another prominent feature of the regression model was the contribution of gender. Postoperative urinary fluoride excretion was significantly (P < 0.05) greater in females than males, who excreted less fluoride postoperatively than expected on the basis of their preoperative excretion and dose of halothane. Despite this, CTF exhalation by the sexes was similar. However, CTF is an index of halothane reduction at the time of breath sampling, whereas urinary fluoride reflects the total amount of halothane reduced, including metabolism during the postoperative period. Halothane is highly lipophilic, having a fat:blood partition coefficient of 60 at physiological temperature,2S and there is a relatively greater proportion of adipose tissue present in females than males. It is therefore possible that females store a larger fraction of a dose of halothane in fat than do males, and that this re-enters the circulation and becomes available to the liver for metabolism in the postoperative period. This would increase postoperative fluoride excretion but not CTF exhalation during surgery. Although the enzyme-inducing drug phenytoin enhanced the rate of CTF exhalation, there was no similar influence on urinary fluoride excretion. Following halothane anaesthesia, the two subjects receiving phenytoin excreted more urinary fluoride than average, but phenytoin was not identified as exerting a significant influence. The influence of diet, skeletal fluoride deposition and release, and the small number of patients may have combined to overshadow any effect of the drug on urinary excretion of reduced halothane metabolites.
Although both smoking and ethanol enhance metabolism of other compounds in man,12 this study revealed no effect on halothane reduction in those who drink ethanol or smoke. Cimetidine and thyroid dysfunction were also not found to influence reductive halothane metabolism, but our ability to detect any such effect is limited because there was only one'patient in each of these categories.
This study provided no explanation of why middle age, obesity and previous exposure are associated with halothane hepatotoxicity. The extent of reductive metabolism in patients was not found to be associated with age, weight, or previous exposure to halothane. It is also noteworthy that paediatric patients exhale similar amounts of CTF to adults following repeated halothane anaesthesia. s Perhaps middle-aged, obese and previously exposed persons are at greater risk because their livers are more susceptible to injury mediated by reduced halothane metabolites. Alternatively, these individuals may be more likely to express an immune response to liver tissue which has been bound and antigenically modified by halothane metabolites.
